Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims

Teva has a chance to block generic competition until Sept. 1, 2015; high court declines to hear False Claims Act case against Takeda and a challenge to Allergan’s Combigan patent.